Advanced search
1 file | 2.15 MB

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer

(2016) ONCOTARGET. 7(18). p.25241-25250
Author
Organization
Abstract
Background: Genetic intratumoral heterogeneity (ITH) hinders biomarker development in metastatic clear cell renal cancer (mccRCC). Epigenetic relative to genetic ITH or the presence of consistent epigenetic changes following targeted therapy in mccRCC have not been evaluated. The aim of this study was to determine methylome/genetic ITH and to evaluate specific epigenetic and genetic changes associated with sunitinib therapy. Patients and methods: Multi-region DNA sampling performed on sequential frozen pairs of primary tumor tissue from 14 metastatic ccRCC patients, in the Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients with Metastatic Renal Cancer: a Pilot Phase II Study (SuMR; ClinicalTrials.gov identifier: NCT01024205), at presentation (biopsy) and after 3-cycles of 50mg sunitinib (nephrectomy). Untreated biopsy and nephrectomy samples before and after renal artery ligation were controls. Ion Proton sequencing of 48 key ccRCC genes, and MethylCap-seq DNA methylation analysis was performed, data was analysed using the statistical computing environment R. Results: Unsupervised hierarchical clustering revealed complete methylome clustering of biopsy and three nephrectomy samples for each patient (14/14 patients). For mutational status, untreated biopsy and all treated nephrectomy samples clustered together in 8/13 (61.5%) patients. The only methylation target significantly altered following sunitinib therapy was VHL promoter region 7896829 which was hypermethylated with treatment (FDR=0.077, P<0.001) and consistent for all patients (pre-treatment 50% patients had VHL mutations, 14% patients VHL hypermethylation). Renal artery ligation did not affect this result. No significant differences in driver or private mutation count was found with sunitinib treatment. Conclusions: Demonstration of relative methylome homogeneity and consistent VHL hypermethylation, after sunitinib, may overcome the hurdle of ITH present at other molecular levels for biomarker research.
Keywords
methylation, heterogeneity, mutations, renal cancer, VHL, LONG-TERM EXPOSURE, PTEN GENE, EVOLUTION, CARCINOMA, VARIANTS, HETEROGENEITY, EXPRESSION, ALGORITHM, TISSUE, MODEL

Downloads

  • Dynamic epigentic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.15 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Stewart, Grant D, Thomas Powles, Christophe Van Neste, Alison Meynert, Fiach O’Mahony, Alexander Laird, Dieter Deforce, et al. 2016. “Dynamic Epigenetic Changes to VHL Occur with Sunitinib in Metastatic Clear Cell Renal Cancer.” Oncotarget 7 (18): 25241–25250.
APA
Stewart, G. D., Powles, T., Van Neste, C., Meynert, A., O’Mahony, F., Laird, A., Deforce, D., et al. (2016). Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer. ONCOTARGET, 7(18), 25241–25250.
Vancouver
1.
Stewart GD, Powles T, Van Neste C, Meynert A, O’Mahony F, Laird A, et al. Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer. ONCOTARGET. 2016;7(18):25241–50.
MLA
Stewart, Grant D, Thomas Powles, Christophe Van Neste, et al. “Dynamic Epigenetic Changes to VHL Occur with Sunitinib in Metastatic Clear Cell Renal Cancer.” ONCOTARGET 7.18 (2016): 25241–25250. Print.
@article{7902008,
  abstract     = {Background: Genetic intratumoral heterogeneity (ITH) hinders biomarker development in metastatic clear cell renal cancer (mccRCC). Epigenetic relative to genetic ITH or the presence of consistent epigenetic changes following targeted therapy in mccRCC have not been evaluated. The aim of this study was to determine methylome/genetic ITH and to evaluate specific epigenetic and genetic changes associated with sunitinib therapy. 
Patients and methods: Multi-region DNA sampling performed on sequential frozen pairs of primary tumor tissue from 14 metastatic ccRCC patients, in the Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients with Metastatic Renal Cancer: a Pilot Phase II Study (SuMR; ClinicalTrials.gov identifier: NCT01024205), at presentation (biopsy) and after 3-cycles of 50mg sunitinib (nephrectomy). Untreated biopsy and nephrectomy samples before and after renal artery ligation were controls. Ion Proton sequencing of 48 key ccRCC genes, and MethylCap-seq DNA methylation analysis was performed, data was analysed using the statistical computing environment R. 
Results: Unsupervised hierarchical clustering revealed complete methylome clustering of biopsy and three nephrectomy samples for each patient (14/14 patients). For mutational status, untreated biopsy and all treated nephrectomy samples clustered together in 8/13 (61.5\%) patients. The only methylation target significantly altered following sunitinib therapy was VHL promoter region 7896829 which was hypermethylated with treatment (FDR=0.077, P{\textlangle}0.001) and consistent for all patients (pre-treatment 50\% patients had VHL mutations, 14\% patients VHL hypermethylation). Renal artery ligation did not affect this result. No significant differences in driver or private mutation count was found with sunitinib treatment. 
Conclusions: Demonstration of relative methylome homogeneity and consistent VHL hypermethylation, after sunitinib, may overcome the hurdle of ITH present at other molecular levels for biomarker research.},
  author       = {Stewart, Grant D and Powles, Thomas and Van Neste, Christophe and Meynert, Alison and O'Mahony, Fiach and Laird, Alexander and Deforce, Dieter and Van Nieuwerburgh, Filip and Trooskens, Geert and Van Criekinge, Wim and De Meyer, Tim and Harrison, David J},
  issn         = {1949-2553},
  journal      = {ONCOTARGET},
  language     = {eng},
  number       = {18},
  pages        = {25241--25250},
  title        = {Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer},
  url          = {http://dx.doi.org/10.18632/oncotarget.8308},
  volume       = {7},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: